BioCentury | Oct 8, 2020
Product Development

Next up for Cytokinetics: readout in CV setting that sparked BMS’s $13B MyoKardia takeout

...large Phase III PARADIGM-HF trial.Additional data from GALACTIC-HF are expected to be presented at the American Heart Association...
BioCentury | Nov 19, 2019
Company News

Nov. 19 Company Quick Takes: Medicines Co. gains on buyout rumor; plus Samsung's biosimilar under review and Zelluna-Glycostem

...the company presented data from two studies of inclisiran, its siRNA against PCSK9, at the American Heart Association...
BioCentury | Nov 18, 2019
Clinical News

Heart failure notches another win as Merck, Bayer's sGC stimulator meets in Phase III

...Off Race for SGLT2s in Heart Failure" ). Detailed data from DAPA-HF, presented at the American Heart Association...
BioCentury | Nov 12, 2019
Clinical News

Safety concerns overshadow efficacy highlights in MyoKardia’s cardiomyopathy data

...therapeutic window could bring safety risks. In two presentations released in advance of the 2019 American Heart Association’s...
BioCentury | Sep 25, 2019
Clinical News

RNAi therapy hits cholesterol endpoints in two more Phase IIIs ahead of Medicines Co.'s submission

...trials. Detailed data from ORION-9 and ORION-10 will be presented on Nov. 16 at the American Heart Association...
BioCentury | Sep 13, 2019
Clinical News

Sept. 12 Clinical Quick Takes: Celgene meets in Phase III for AML maintenance therapy; plus Roche, Tocagen, Adverum, Daiichi Sankyo, Apple, Navitor

...NIH on the long-term Apple Women's Health Study; with Brigham and Women's Hospital and the American Heart Association...
BioCentury | Aug 31, 2019
Product Development

Privacy, transparency and consent

...are backed by Xcertia’s founding members, which include the American Medical Association (AMA) and the American Heart Association...
...see “ Criteria of Demarcation .” Companies and Institutions Mentioned Akiri Inc., Foster City, Calif. American Heart Association...
BioCentury | Mar 22, 2019
Clinical News

Amarin's Vascepa reduces total CV events by 30% in REDUCE-IT

...the primary endpoint. The biotech presented detailed data from the trial in November at the American Heart Association...
BioCentury | Feb 15, 2019
Tools & Techniques

Heartening predictors in diabetes

...much heated debate, coronary calcium was finally accepted as a good biomarker” in the 2018 American Heart Association...
...Companies and Institutions Mentioned American College of Cardiology, Washington, D.C. American Diabetes Association, Arlington, Va. American Heart Association...
BioCentury | Jan 17, 2019
Finance

Public funding highlights

...total of $400 million in 2018. Strategy Nov. 9 Paul G. Allen Frontiers Group ; American Heart Association...
Items per page:
1 - 10 of 504
BioCentury | Oct 8, 2020
Product Development

Next up for Cytokinetics: readout in CV setting that sparked BMS’s $13B MyoKardia takeout

...large Phase III PARADIGM-HF trial.Additional data from GALACTIC-HF are expected to be presented at the American Heart Association...
BioCentury | Nov 19, 2019
Company News

Nov. 19 Company Quick Takes: Medicines Co. gains on buyout rumor; plus Samsung's biosimilar under review and Zelluna-Glycostem

...the company presented data from two studies of inclisiran, its siRNA against PCSK9, at the American Heart Association...
BioCentury | Nov 18, 2019
Clinical News

Heart failure notches another win as Merck, Bayer's sGC stimulator meets in Phase III

...Off Race for SGLT2s in Heart Failure" ). Detailed data from DAPA-HF, presented at the American Heart Association...
BioCentury | Nov 12, 2019
Clinical News

Safety concerns overshadow efficacy highlights in MyoKardia’s cardiomyopathy data

...therapeutic window could bring safety risks. In two presentations released in advance of the 2019 American Heart Association’s...
BioCentury | Sep 25, 2019
Clinical News

RNAi therapy hits cholesterol endpoints in two more Phase IIIs ahead of Medicines Co.'s submission

...trials. Detailed data from ORION-9 and ORION-10 will be presented on Nov. 16 at the American Heart Association...
BioCentury | Sep 13, 2019
Clinical News

Sept. 12 Clinical Quick Takes: Celgene meets in Phase III for AML maintenance therapy; plus Roche, Tocagen, Adverum, Daiichi Sankyo, Apple, Navitor

...NIH on the long-term Apple Women's Health Study; with Brigham and Women's Hospital and the American Heart Association...
BioCentury | Aug 31, 2019
Product Development

Privacy, transparency and consent

...are backed by Xcertia’s founding members, which include the American Medical Association (AMA) and the American Heart Association...
...see “ Criteria of Demarcation .” Companies and Institutions Mentioned Akiri Inc., Foster City, Calif. American Heart Association...
BioCentury | Mar 22, 2019
Clinical News

Amarin's Vascepa reduces total CV events by 30% in REDUCE-IT

...the primary endpoint. The biotech presented detailed data from the trial in November at the American Heart Association...
BioCentury | Feb 15, 2019
Tools & Techniques

Heartening predictors in diabetes

...much heated debate, coronary calcium was finally accepted as a good biomarker” in the 2018 American Heart Association...
...Companies and Institutions Mentioned American College of Cardiology, Washington, D.C. American Diabetes Association, Arlington, Va. American Heart Association...
BioCentury | Jan 17, 2019
Finance

Public funding highlights

...total of $400 million in 2018. Strategy Nov. 9 Paul G. Allen Frontiers Group ; American Heart Association...
Items per page:
1 - 10 of 504